What is the official website of Molecular Devices ?

The official website of Molecular Devices is https://www.moleculardevices.com.

What is Molecular Devices's cybersecurity risk score?

Molecular Devices has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Molecular Devices experienced?

According to Rankiteo, Molecular Devices currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Molecular Devices been affected by any supply chain cyber incidents ?

According to Rankiteo, Molecular Devices has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Molecular Devices have SOC 2 Type 1 certification ?

According to Rankiteo, Molecular Devices is not certified under SOC 2 Type 1.

Does Molecular Devices have SOC 2 Type 2 certification ?

According to Rankiteo, Molecular Devices does not hold a SOC 2 Type 2 certification.

Does Molecular Devices comply with GDPR ?

According to Rankiteo, Molecular Devices is not listed as GDPR compliant.

Does Molecular Devices have PCI DSS certification ?

According to Rankiteo, Molecular Devices does not currently maintain PCI DSS compliance.

Does Molecular Devices comply with HIPAA ?

According to Rankiteo, Molecular Devices is not compliant with HIPAA regulations.

Does Molecular Devices have ISO 27001 certification ?

According to Rankiteo,Molecular Devices is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Molecular Devices operate in ?

Molecular Devices operates primarily in the Biotechnology Research industry.

How many employees does Molecular Devices have ?

Molecular Devices employs approximately 745 people worldwide.

Does Molecular Devices own any subsidiaries ?

Molecular Devices presently has no subsidiaries across any sectors.

How many LinkedIn followers does Molecular Devices have ?

Molecular Devices's official LinkedIn profile has approximately 43,965 followers.

What is the NAICS classification code for Molecular Devices ?

Molecular Devices is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does Molecular Devices have a Crunchbase profile ?

No, Molecular Devices does not have a profile on Crunchbase.

Does Molecular Devices have a LinkedIn profile ?

Yes, Molecular Devices maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/molecular-devices.

How many cybersecurity incidents has Molecular Devices experienced ?

As of July 20, 2026, Rankiteo reports that Molecular Devices has not experienced any cybersecurity incidents.

How many peer or competitor companies does Molecular Devices have ?

Molecular Devices has an estimated 4,724 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Molecular Devices

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

Molecular Devices Vendor Cyber Rating & Cyber Score

moleculardevices.com

Add Your Compliance Badge

Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications. Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class

Molecular Devices A.I CyberSecurity Scoring

Scoring History

Molecular Devices

Molecular Devices CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Molecular Devices Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Molecular Devices

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Molecular Devices in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Molecular Devices in 2026.

Incident Types Molecular Devices vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Molecular Devices in 2026.

Incident History - Molecular Devices (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Molecular Devices Subsidiaries

Molecular Devices

Biotechnology Research

Website: https://www.moleculardevices.com

Company Size: 745

Danaher CorporationMedical Equipment Manufacturing

Beckman Coulter DiagnosticsMedical Equipment Manufacturing

Beckman Coulter Dx North AmericaMedical Equipment Manufacturing

Beckman Coulter Dx BrasilFabricação de instrumentos e materiais para uso médico e odontológico e de artigos ópticos

Beckman Coulter Dx EEMEAتصنيع المعدات الطبية

Beckman Coulter Dx LATAMFabricação de instrumentos e materiais para uso médico e odontológico e de artigos ópticos

Beckman Coulter Dx Asia PacificMedical Equipment Manufacturing

한국벡크만쿨터의료장비 제조

Pall CorporationManufacturing

Pall - Energy+Machinery Manufacturing

Aria FiltraEnvironmental Services

Pall - Food & BeverageFood and Beverage Services

Pall - AerospaceAviation and Aerospace Component Manufacturing

Pall - Energy+Machinery Manufacturing

Pall - MicroelectronicsAppliances, Electrical, and Electronics Manufacturing

CytivaBiotechnology Research

Pall Medical, part of CytivaMedical Equipment Manufacturing

Cytiva LATAMPesquisa biotecnológica

CepheidBiotechnology Research

Leica MicrosystemsMedical Equipment Manufacturing

Leica Microsystems MedicalHospitals and Health Care

Leica BiosystemsMedical Device

Leica Biosystems EMEAMedical Equipment Manufacturing

Beckman Coulter Life SciencesBiotechnology Research

Beckman Coulter Life Sciences India, SWA, METAIBiotechnology Research

Beckman Coulter Life Sciences BrazilBiotechnology Research

Beckman Coulter Life Sciences TASK RegionBiotechnology Research

Beckman Coulter Life Sciences LATAMBiotechnology Research

Beckman Coulter Life Sciences - China生物技术研究

Beckman Coulter Life Sciences RussiaИсследования в сфере биотехнологий

Integrated DNA TechnologiesBiotechnology Research

CRISPR genome editing by IDTBiotechnology Research

SCIEXBiotechnology Research

SCIEX Food & Environmental Testing SolutionsBiotechnology Research

SCIEX Biopharma & Pharma SolutionsBiotechnology Research

SCIEX Omics SolutionsBiotechnology

SCIEX Forensic Testing SolutionsBiotechnology Research

SCIEX Service & SupportMedical Equipment Manufacturing

SCIEX Clinical ApplicationsMedical Equipment Manufacturing

SCIEX LatinoaméricaPesquisa biotecnológica

RadiometerMedical Equipment Manufacturing

AbcamBiotechnology Research

PhenomenexBiotechnology Research

Phenomenex - EMEABiotechnology

Danaher Life SciencesBiotechnology Research

Beckman Coulter Diagnostics EuropeMedical Equipment Manufacturing

MammotomeMedical Equipment Manufacturing

AldevronBiotechnology Research

GenedataBiotechnology Research

ジーンデータ（株）/ Genedata KKバイオテクノロジー研究

IDBSSoftware Development

PolarSoftware Development

HemoCue ABMedical Equipment Manufacturing

Beckman Coulter Dx India & SWAMedical Equipment Manufacturing

Beckman Coulter Dx TurkeyTıbbi Ekipman İmalatı

Beckman Coulter Dx Eastern EuropeVýroba zdravotnických prostředků

Danaher India Development CenterIT System Custom Software Development

Beckman Coulter Dx China生物技术研究

Danaher DiagnosticsMedical Equipment Manufacturing

Clone Screening | Molecular DevicesBiotechnology Research

FLIPR Penta Drug Screening | Molecular DevicesBiotechnology Research

3D Biology | Molecular DevicesBiotechnology Research

Molecular Devices China生物技术研究

High-Content Imaging & Analysis | Molecular DevicesBiotechnology Research

Loading…

Molecular Devices Similar Companies

Syneos Health

cb syneoshealth.com

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

Thermo Fisher Scientific

thermofisher.com

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

bioMérieux

biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

Genentech

gene.com

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Loading…

NEWS

Molecular Devices CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 31, 2025 06:26 AM

IISc Develops Molecular-Scale Technology that Mimics Brain Functions

Scientists at the Indian Institute of Science have developed molecular-scale electronic devices capable of performing multiple computing functions within...

Read Article

November 19, 2025 08:00 AM

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Advancing next-generation IMC workflows with class-leading HCR imaging technologies for greater sensitivity and flexibility.

Read Article

March 18, 2025 07:00 AM

Quantum Computing Explained

These computers work by harnessing quantum physics — the strange, often counterintuitive laws that govern the universe at its smallest scales...

Read Article

April 11, 2024 07:00 AM

New molecular device could revolutionise medical and material engineering

Scientists from The University of Manchester have developed a first-of-its-kind molecular device that uses force to control the release of multiple small...

Read Article

September 03, 2021 07:00 AM

Groundbreaking brain-inspired memory device for semiconductor design

Researchers at the NUS have developed a novel brain-inspired device that could facilitate the transformation of semiconductor design.

Read Article

August 12, 2021 07:00 AM

Katie Sautter: building materials for a quantum future

In graduate school, Argonne postdoctoral researcher Katie Sautter learned to master a machine that builds bits of matter one atomic layer at...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12484

SUMMARY

A vulnerability in keras-team/keras version 3.15.0 allows unsafe deserialization of attacker-controlled PyTorch pickle data through the public `keras.layers.TorchModuleWrapper.from_config` method. This method invokes `torch.load(..., weights_only=False)` without requiring an explicit unsafe opt-in, such as a `safe_mode=False` parameter. When called outside a `SafeModeScope(True)` context, the absence of an ambient safe mode state permits unsafe deserialization by default. This issue can lead to arbitrary code execution if untrusted Keras layer configurations are processed using this method. The vulnerability arises because the method does not enforce safe deserialization practices unless explicitly guarded by Keras safe mode.

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.0/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://huntr.com/bounties/ab14df49-13b5-4442-b754-3189430bfa28

CVE-2026-64186

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: iommu/amd: Remove latent out-of-bounds access in IOMMU debugfs In iommu_mmio_write() and iommu_capability_write(), the variables dbg_mmio_offset and dbg_cap_offset are declared as int. However, they are populated using kstrtou32_from_user(). If a user provides a sufficiently large value, it can become a negative integer. Prior to this patch, the AMD IOMMU debugfs implementation was already protected by different mechanisms. 1. #define OFS_IN_SZ 8 ensures the user string <= 8 bytes, so e.g. 0xffffffff isn't a valid input. if (cnt > OFS_IN_SZ) return -EINVAL; 2. Implicit type promotion in iommu_mmio_write(), dbg_mmio_offset is int and iommu->mmio_phys_end is u64 if (dbg_mmio_offset > iommu->mmio_phys_end - sizeof(u64)) return -EINVAL; 3. The show handlers would currently catch the negative number and refuse to perform the read. Replace kstrtou32_from_user() with kstrtos32_from_user() to parse the input, and check for negative values to explicitly prevent out-of-bounds memory accesses directly in iommu_mmio_write() and iommu_capability_write().

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-64185

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: sysfs: don't remove existing directory on update failure When sysfs_update_group() is called for a named group and create_files() fails (e.g. -ENOMEM), internal_create_group() calls kernfs_remove(kn) on the group directory. In the update path, kn was obtained via kernfs_find_and_get() and refers to a directory that already existed before this call. Removing it silently destroys a sysfs group that the caller did not create. Only remove the directory if we created it ourselves. On update failure the directory remains as it is left empty by remove_files() inside create_files(), but can be repopulated by a retry.

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-64184

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: mm/damon/sysfs-schemes: call missing mem_cgroup_iter_break() damon_sysfs_memcg_path_to_id() breaks mem_cgroup_iter() loop without calling mem_cgroup_iter_break(). This leaks the cgroup reference. Fix the issue by calling mem_cgroup_iter_break() before the break. The issue was discovered [1] by Sashiko.

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-64183

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: efi: Allocate runtime workqueue before ACPI init Since commit 5894cf571e14 ("acpi/prmt: Use EFI runtime sandbox to invoke PRM handlers") ACPI PRM calls are delegated to a workqueue which runs in a kernel thread, making it easier to detect and mitigate faulting memory accesses performed by the firmware. Rafael reports that such PRM accesses may occur before efisubsys_init() executes, which is where the workqueue is allocated, leading to NULL pointer dereferences. Since acpi_init() [which triggers the early PRM accesses] executes as a subsys_initcall() as well, and has its own dependencies that may be sensitive to initcall ordering, deferring acpi_init() is not an option. So instead, split off the workqueue allocation into its own postcore initcall, as this is the only missing piece to allow EFI runtime calls to be made. This ensures that EFI runtime call (including PRM calls) are accessible to all code running at subsys_initcall() level.

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…